Lung cancer is the most frequent malignancy worldwide and one of the main causes of cancer-related death.1 Approximately 80%-85% of lung carcinomata are non-small cell lung (NSCLC) carcinoma, the three main types of which are adenocarcinoma, originating from mucus producing cells, squamous cell carcinoma (SCC) originating in cells that cover the airway surface and large cell carcinoma, referring to the size of the cells from which they originate.2 An additional 15%-20% of carcinomata are derived from neuro-endocrine cells and are termed small cell lung carcinoma (SCLC).2 Depending upon the disease extent at the time of diagnosis and the subtype type of lung cancer, NSCLC versus SCLCL, the treatment strategy and prognosis may vary significantly. Over the past two decades, FDG PET/CT imaging has proven to be an effective imaging modality for assessing the disease extent at the time of diagnosis of a wide variety of human malignancies, including lung carcinoma.3 Here we, provide an update on the role of this imaging modality for staging of Lung carcinoma. A search was performed on Pubmed using the search terms “non-small cell lung carcinoma”, “small cell lung carcinoma”, “NSCLC”, “SCLCL”, “18F-fluoro-deoxyglucose or FDG”, “positron emission tomography”, “PET”, “lung”, “stage”, “staging”, “lymph node metastases”, “lymph node involvement”, “metastasis”, “metastases”, “limited disease” and “extensive disease”. Radiomic-features derived from the primary tumor FDG-PET volume may also provide relevant information on the presence or absence of occult LN-involvement. However, prior to their clinical implementation, these data will need to be confirmed in prospective studies using a well standardized methodology with external validation.